Promise Bio, a company pioneering precision medicine solutions using epiproteomics and artificial intelligence, today announced the launch of the Frontier Epiproteomic Innovation Grant, an R&D access ...
The journey towards circular high-performance composites begins with one core question: why redesign an already mature class of materials? To set the scene, we asked the consortium to describe the ...
Commercial sponsorship integrates EvE Bio's growing field‑defining "pharmome" map - 385,572 rigorously confirmed drug–target interactions across 159 validated targets - into DrugBank's intelligence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results